| Anthrax AV7909 Liquid vs Lyophilized (NCT04660201) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-05-25 |
| A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (NCT01624532) | Green Cross Corporation | 2021-07-14 |
| Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI) (NCT04320485) | InBios International, Inc. | 2020-03-25 |
| A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (NCT04148118) | BlueWillow Biologics | 2020-01-08 |
| Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (NCT04067011) | Emergent BioSolutions | 2019-08-12 |
| VELOCITY: An Anthrax Vaccine Clinical Study (NCT03877926) | Emergent BioSolutions | 2019-03-11 |
| Febrile Whole Blood Specimen Collection and Testing (NCT03498027) | MRI Global | 2018-07-26 |
| BARDA Securing Anthrax Immunity For the Elderly (NCT03518125) | Biomedical Advanced Research and Development Authority | 2018-05-09 |
| PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine (NCT02239172) | Fraunhofer, Center for Molecular Biotechnology | 2014-08-01 |
| A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels (NCT01770743) | Emergent BioSolutions | 2013-01-01 |
| Ciprofloxacin BioThrax Co-Administration Study (NCT01753115) | Emergent BioSolutions | 2012-12-01 |
| Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults (NCT01491607) | Emergent BioSolutions | 2011-11-01 |
| Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects (NCT01265745) | PharmAthene, Inc. | 2010-12-01 |
| Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) (NCT01202695) | Emergent BioSolutions | 2010-08-01 |
| Ph1 Study of Valortim and Ciprofloxacin in Humans (NCT00964561) | PharmAthene, Inc. | 2009-08-01 |
| Ph1 Study of Valortim and Doxycycline in Humans (NCT00964834) | PharmAthene, Inc. | 2009-07-01 |
| Efficacy and Safety of Anthrax Vaccine, GC1109 (NCT01867957) | Seoul National University Hospital | 2009-02-01 |
| Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) (NCT00845650) | Emergent BioSolutions | 2009-02-01 |
| Anthrax Vaccine Clinical Trials (NCT00114621) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2004-09-08 |
| VHA Clinicians and Bioterror Events: Interactive Web-based Learning (NCT00123396) | US Department of Veterans Affairs | 2004-08-01 |
| Trial of rPA-102 Vaccine in Healthy Adult Volunteers (NCT00100724) | VaxGen | 2004-04-01 |
| Anthrax-rPA: Safety, Tolerability, Immunogenicity (NCT00063843) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-07-01 |
| A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults (NCT00057525) | DynPort Vaccine Company LLC, A GDIT Company | 2003-04-01 |
| Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients (NCT00050310) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-10-31 |